Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $95,000.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 5,000 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $19.00, for a total value of $95,000.00. Following the sale, the insider owned 411,775 shares of the company’s stock, valued at $7,823,725. This represents a 1.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $18.00, for a total value of $198,000.00.

Adaptive Biotechnologies Stock Down 0.8%

Shares of Adaptive Biotechnologies stock traded down $0.14 during trading hours on Monday, hitting $17.46. 2,837,060 shares of the company’s stock traded hands, compared to its average volume of 2,101,648. The stock has a 50 day simple moving average of $14.62 and a 200-day simple moving average of $15.63. The company has a market cap of $2.79 billion, a PE ratio of -52.91 and a beta of 2.16. Adaptive Biotechnologies Corporation has a twelve month low of $9.96 and a twelve month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. During the same period last year, the firm earned ($0.20) earnings per share. The company’s revenue was up 35.1% on a year-over-year basis. As a group, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Wall Street Analysts Forecast Growth

ADPT has been the topic of a number of recent research reports. BTIG Research restated a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. JPMorgan Chase & Co. reduced their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. TD Cowen raised their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and a consensus target price of $19.57.

Institutional Trading of Adaptive Biotechnologies

Several hedge funds have recently bought and sold shares of ADPT. Westfield Capital Management Co. LP bought a new stake in Adaptive Biotechnologies in the 4th quarter valued at about $65,942,000. Price T Rowe Associates Inc. MD lifted its position in Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after purchasing an additional 3,299,635 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Adaptive Biotechnologies by 84.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after buying an additional 2,731,648 shares during the period. Invesco Ltd. increased its stake in Adaptive Biotechnologies by 248.8% during the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after buying an additional 2,216,595 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in Adaptive Biotechnologies by 544.0% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after buying an additional 2,062,282 shares during the period. 99.17% of the stock is currently owned by institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.